Overview

Measure and monitor gastroesophageal pH with Bravo™

Bravo™ calibration-free provides information to help establish the GERD diagnosis.1
 
  • Up to 70 percent of patients with GERD do not have evidence of erosive changes on endoscopy.2
  • The system provides greater sensitivity than endoscopy and higher specificity than therapeutic trials with PPIs.1
  • Patients maintain regular diet and activities during the procedure, so testing is done under normal physiologic conditions.3
  • Tolerance and satisfaction with catheter-free pH monitoring are high in patients who had previously failed catheter-based pH; catheter-free pH monitoring assists in the definitive diagnosis of GERD in this group.4

Bravo™ calibration-free product brochure

Bravo™ is used as part of the complete assessment of GERD.

View Brochure

1 in 3 patients referred with ongoing symptoms while using PPIs doesn't have GERD.5

There are many recent advances in the diagnosis and management of GERD. Prolonged wireless pH monitoring has value on clinical reflux monitoring to enable the assessment of predominant exposure patterns and aid in the diagnosis of GERD.1

Among patients with heartburn, endoscopy with ambulatory reflux monitoring (off PPI) optimizes cost-effective management.6

The most cost-effective diagnostic approach to managing patients with typical
GERD symptoms of heartburn that lack alarm symptoms and fail an empiric PPI is to offer endoscopy with ambulatory reflux monitoring followed by a trial of PPI discontinuation for patients without erosive findings.6

See the current GERD diagnosis and management guidelines from the American College of Gastroenterology and the American Gastroenterology Association.

Our product portfolio 

Bravo™ calibration-free reflux capsule

Use the Bravo™ calibration-free reflux testing system for gastroesophageal pH measurement and monitoring of gastric reflux. The capsule can be attached following either endoscopy or manometry and doesn't require pH calibration. 

Bravo™ reflux recorder

The patient wears the recorder for up to 96 hours while the capsule is detecting reflux events, to record reflux data and patient activity.

Reflux software v6.1

Our reflux software supports the upload and analysis of pH and pH-impedance data collected from the Bravo™ reflux recorder and the Digitrapper™ reflux recorder. The reflux software also allows for extended recording times up to 96 hours5 via the Bravo™ calibration-free reflux testing system.

Order Information
ORDER CODE DESCRIPTION UNIT OF MEASURE QUANTITY
FGS-0635 Bravo™ calibration-free reflux capsule with delivery system Pack 5
FGS-0634 Bravo™ reflux recorder (includes carry case, charger, carry strap, USB cable, document mini CD) Each 1
409990126 Reflux software v6.1 kit Each 1

Order Information

TRANSFORM ESOPHAGEAL CARE

Our comprehensive solutions can assist you in the assessment and treatment of esophageal patients.

Patient resources

Find patient information about GERD, acid reflux, and related treatments and therapies.

SOFTWARE UPDATES

Reflux Reader v6.1 Software Updates

Contact a representative to download the latest reflux reader software.

  • 1. Hirano I, Zhang Q, Pandolfino JE, et al. Four-day Bravo™ reflux testing system pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol and Hepatol. 2005;3(11):1083–1088.

  • 2. Vaezi M, Zehrai A, and Yuksel E. Testing for refractory gastroesophageal reflux disease. American Society for Gastrointestinal Endoscopy ASGE Leading Edge. 2012;2(2):1–13.

  • 3. Tseng D, Rizvi AZ, Fennerty MB, et al. Forty-eight hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastro Surgery. 2005;9(8):1043–1052.

  • 4. Sweiss R, Fox M, Anggiansah R, et al. Patient acceptance and clinical impact of Bravo™ monitoring in patients with previous failed catheter-based studies. Aliment Pharmacology and Therapeutics. 2009 Mar 15;29(6):669–676.

     View Abstract
  • 5. Herregods, T. V. K., et al. Patients with refractory reflux symptoms often do not have GERD: Neurogastroenterology & Motility. 2015;27(9): 1267–1273.

  • 6. Yadlapati, R., G y awali, C. P., Pandolfino, J.E., Chang, K., Kahrilas, P. J., Katz, P. 0., Katzka, D., Komanduri, S., Lipham, J., Menard-Katcher, P., Raman Muthusamy, V., Richter, J., Sharma, V. K., Vaezi, M. F., and Wani, S. (2022). Aga clinical practice update on the personalized approach to the evaluation and management of gerd: Expert review. Clinical Gastroenterology and Hepatology. 20(5), 984–994. https://doi.org/10.1016/j.cgh.2022.01.025